| Prev Close | 2.80 |
| Day Low/High | 2.71 / 2.85 |
| 52 Wk Low/High | 2.24 / 7.72 |
Genprex, Inc. (GNPX)
2.79
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 47.53B |
| Market Cap | 133.08M |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Roll the Dice on This Bounce
This has given investors an opportunity to load up on small speculative names I love over the next 12 to 18 months.
Inspect the Fingerprints on the Genprex Offering, Before Making a Move
Let's get out the magnifying glass and examine GNPX's selling of 4 million shares and the hit it took on Tuesday.
Let's Look at the Big Picture of Genprex
After GNPX's private placement on Tuesday, I spoke with the CEO, Rodney Varner. Here's what I found out and what my views are on the developer of cancer and diabetes therapies.
We May Have a Trade in Front of Us Right Here for Genprex
The options don't give a ton of choices, but I like the buy-write.
Let the Pols Trade Barbs, We'll Trade Stocks ... and Look to the Futures
As the pundits decide who won, I'm looking at these biotech names with a focus on Myovant Sciences.
Immatics Is a Biotech Where Patient Investors Could Be Handsomely Rewarded
2021 will be a big year, upside is at least twice the current valuation, and downside is limited to 10% from current levels.
This Biotech Appears to Have the Right Formula for Investors
After reviewing the rally, let's zero in on one biotech name, Genprex, and where it appears to be going.
I Like the Technical Setup in Genprex
Overall I believe GNPX shapes up well in the biotech space.
Now's the Time for Companies to Mix It Up
Firms should be using their high stock price to grab other businesses to expand, so they're ready when things return to normal.
Sometimes, Stories Do Come True
Two names I've talked about, AYRO and GNPX, saw their stories get closer to reality on Tuesday.
Upwork Shares Are Breaking Out Higher Today
The initial target here is $16 with a secondary target of $17.50 on this breakout, with a time frame of a month or less.
This Mistake Could Pay You Dearly
A desperate deal by Genprex could spell opportunity for investors. Here's how.
Genprex Is Soaring - And There's a One Word Reason Why
The small biotech's market cap sits at $125 million, the low end of what I believe is fair.
Genprex Has the Right Formula for a Trade
I've followed this name before it went public, and it's got some potentially promising treatments in its pipeline.
Those Golden Rule
If you want a perfect example of this, look at two recent capital raises: one from Tesla and one from Genprex over the past week.
Genprex: The Bad and the Good of Capital Raises
For those who love a roll of the dice, GNPX may be worth a closer look.
How to Buy the Right Broken Stocks
I hold two broken stocks at the moment: GreenSky and Genprex.
Innoviva Is Attractive Play in Biotech
Strong balance sheet and royalties are big positives for Innoviva.
How to Play Molina Health
Shares are finally reversing post-earnings slide in February.